Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hematologic malignancies: selected abstracts and commentary.

M L Grossbard1

  • 1Division of Hematology/Oncology, St. Luke's-Roosevelt Hospital Center, New York, New York 10019, USA. mgrossbard@slrhc.org

The Oncologist
|August 31, 2000
PubMed
Summary

ASCO 2000 highlighted incremental advances in hematologic malignancy treatment, focusing on targeted therapies like STI 571 for chronic myelogenous leukemia and antibody treatments for non-Hodgkin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

131I tositumomab: a viewpoint by Michael L. Grossbard.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Leukemia & lymphoma·2005
Same author

Pancreatic carcinoma with brain metastases: case report and literature review.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2004
Same author

Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.

Anti-cancer drugs·2004
Same author

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

The oncologist·2001
Same author

The expanding frontier of radioimmunotherapy of relapsed Non-hodgkin's lymphoma.

Clinical lymphoma·2001

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • ASCO 2000 meeting provided updates on hematologic malignancy treatments.
  • Advances built incrementally on previous years' findings.
  • Focus remained on targeted therapies and novel treatment modalities.

Framework:

  • STI 571, a tyrosine kinase inhibitor, showed promise in chronic myelogenous leukemia treatment.
  • Monoclonal antibody therapy, including radioimmunoconjugates, was further evaluated for non-Hodgkin's lymphoma.
  • Positron emission tomography (PET) scans' role in lymphoid malignancy staging and follow-up was clarified.

Implementation:

  • Clinical development of STI 571 for chronic myelogenous leukemia.
  • Evaluation of unconjugated and conjugated monoclonal antibodies for non-Hodgkin's lymphoma.
  • Application of PET scans in lymphoid malignancy diagnostics.

Implications:

  • Continued progress in targeted therapy for hematologic cancers.
  • Refined understanding of antibody-based treatments and their efficacy.
  • Improved diagnostic accuracy and patient management through advanced imaging techniques.

Related Experiment Videos